In a rare de­lay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecen­triq/Avastin triple for lung can­cer

Roche’s Genen­tech was sup­posed to get a pri­or­i­ty re­view for its com­bo us­ing Tecen­triq and Avastin plus chemo in front­line lung can­cer cas­es, with a dead­line on the FDA’s de­ci­sion set for Wednes­day. And usu­al­ly, that means a green light is on its way soon­er rather than lat­er.

But that didn’t hap­pen. 

In­stead, the FDA says it will de­lay its de­ci­sion three months so they can take in­to ac­count some new in­for­ma­tion that the agency want­ed to see first.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.